Search company, investor...
AMAG Pharmaceuticals company logo

AMAG Pharmaceuticals

amagpharma.com

Founded Year

1981

Stage

Acq - P2P | Acquired

Valuation

$0000 

About AMAG Pharmaceuticals

AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products. AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.

Headquarters Location

1100 Winter Street

Waltham, Massachusetts, 02451,

United States

617-498-3300

Missing: AMAG Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AMAG Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AMAG Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AMAG Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

AMAG Pharmaceuticals Patents

AMAG Pharmaceuticals has filed 12 patents.

The 3 most popular patent topics include:

  • Androgens and anabolic steroids
  • Estranes
  • Pregnanes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/24/2019

10/26/2021

Progestogens, Androgens and anabolic steroids, Pregnanes, Estranes, Prodrugs

Grant

Application Date

9/24/2019

Grant Date

10/26/2021

Title

Related Topics

Progestogens, Androgens and anabolic steroids, Pregnanes, Estranes, Prodrugs

Status

Grant

Latest AMAG Pharmaceuticals News

Sales of Intravenous Iron Drugs Market is Estimated to hit US$ 6.3 Bn at a CAGR of 8.5% by year 2032-end | Future Market Insights, Inc.

Dec 16, 2022

| Future Market Insights, Inc. Global  Intravenous Iron Drugs Market  was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 6.3 Bn by 2032, finds Fact.MR in a recent market survey. As per the findings of the report, Intravenous Iron Drugs revenue through Ferric Carboxymaltose will garner significant demand in the market as the bulk of revenue will be generated through them. The American Heart Association predicts that by 2035, more than 130 million adults in the United States will have cardiovascular disease. In addition, the Centers for Disease Control and Prevention reports that 0.6 million Americans die each year from heart disease. This information leads directly to the number of hospital admissions. The Ferric Carboxymaltose (FCM) segment led the market for intravenous iron medicines in 2021, with nearly 50% revenue share due to its expanding use, improved performance, and lower cost. It is a parenteral iron medication devoid of dextran which is suggested for the quick and high-dose replacement of depleted iron reserves. This medicine is a stable compound with the benefit of not containing any extraneous ingredients and having a very low immunogenic potential; hence, it poses a very low risk of anaphylactic responses. FCM has a higher effectiveness in terms of boosting hemoglobin levels and has fewer side effects. The tremendous rise may also be attributed to the FDA approval of Injectates in North America as well as its approval outside of North America. The region’s expanding senior population is a primary driver of industry development. According to US Census Bureau forecasts, the number of Americans aged 65 and older would rise from 52 million in 2018 to roughly 95 million by 2060. Furthermore, the overall percentage of people aged 65 and older is projected to increase from 16% to 23%. It may be linked to the presence of a higher incidence of cancer, intestinal illnesses, and renal disease in the specific area. These conditions also are reinforcing its dominance. It has also contributed to the growth of women’s health awareness and the awareness about celiac disease. Competitive Landscape Some of the key players in the global Intravenous Iron Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; and Shield Therapeutics Plc among others. Some of the recent developments in the Intravenous Iron Drugs Market are: In April 2018, AMAG Pharmaceuticals got FDA clearance for a supplementary new drug application for ferumoxytol injection to cover all eligible people with iron-deficiency anaemia (IDA) who cannot tolerate or do not respond to oral iron. In May 2019, Rockwell Medical, Inc. filed a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the Intravenous (I.V.) version of Triferic. In September 2020, Daiichi Sankyo announced the formation of its wholly-owned subsidiary Daiichi Sankyo Vietnam Company Limited. This program was launched in order to strengthen the company’s Asian business platform. More Insights Available Future Market Insights, in its new offering, presents an unbiased analysis of the Intravenous Iron Drugs Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032. The study reveals essential insights on the basis of Product Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types), by Indication (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

AMAG Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was AMAG Pharmaceuticals founded?

    AMAG Pharmaceuticals was founded in 1981.

  • Where is AMAG Pharmaceuticals's headquarters?

    AMAG Pharmaceuticals's headquarters is located at 1100 Winter Street, Waltham.

  • What is AMAG Pharmaceuticals's latest funding round?

    AMAG Pharmaceuticals's latest funding round is Acq - P2P.

  • Who are the investors of AMAG Pharmaceuticals?

    Investors of AMAG Pharmaceuticals include Covis Pharma, Great Point Partners, Vivo Capital, Biomedical Value Fund, LRG Capital Group and 9 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.